|
medpundit |
||
 |
 |
|
Thursday, November 14, 2002The research team found that none of the patients with a low level of cyclin E had died from the disease. It was also noted that the proportion of tumours with high levels of cyclin E increased with the growing severity of the disease. Unlike the C-reactive protein study, this one doesn’t shy away from the numbers: Among 114 patients with stage I breast cancer, none of the 102 patients with low levels of cyclin E in the tumor had died of breast cancer by five years after diagnosis, whereas all 12 patients with a high level of low-molecular-weight cyclin E had died of breast cancer within that period. The authors also have a patent on testing for the protein, but they’ve been much more honest in portraying their results than Dr. Ridker was. Admittedly, the results were in their favor, but they were also careful to temper their enthusiasm in their conclusions. They point out that the data is based on a small sample, and they caution that more work has to be done before it can be applied to larger populations. Proof that you can hold patents on your research topics and still maintain your integrity. posted by Sydney on 11/14/2002 07:45:00 AM 0 comments 0 Comments: |
|
